TY  - JOUR
T1  - POstmenopausal estrogens—opposed, unopposed, or none of the above
AU  - Willett WC, Colditz G, Stampfer M
Y1  - 2000/01/26
N1  - 10.1001/jama.283.4.534
JO  - JAMA
SP  - 534
EP  - 535
VL  - 283
IS  - 4
N2  - 
Addition of progestin to estrogen largely mitigates the increased risk
of endometrial cancer,2 and combination therapy
(opposed estrogen) has become the standard hormonal regimen for women with
a uterus. The impact of combined estrogen and progestin on risk of breast
cancer has been controversial. Although protective effects analogous to those
for endometrial cancer have been hypothesized for breast cancer, cyclical
use of progestin to simulate normal menstrual cycles increases mitotic activity
in the breast.3

SN  - 0098-7484
M3  - doi: 10.1001/jama.283.4.534
UR  - http://dx.doi.org/10.1001/jama.283.4.534
ER  -